Download PDF
Nuklearmedizin 2020; 59(04): 332-334
DOI: 10.1055/a-1132-5104
Case Report

Different manifestations detected with 68Ga-DOTATOC PET/CT in patients with Von Hippel-Lindau disease: A case report

Pierre Meneret
1   Nuclear Medicine, Centre Eugene Marquis, Rennes, France
,
Antoine Girard
1   Nuclear Medicine, Centre Eugene Marquis, Rennes, France
,
Mael Pagenault
2   Gastroenterology, CHU Rennes, France
,
Laurent Riffaud
3   Neurosurgery, CHU Rennes, France
,
Xavier Palard-Novello
4   Centre Eugene Marquis, Rennes, France
› Author Affiliations
› Further Information
    Permissions and Reprints

Introduction

von-Hippel-Lindau (VHL) disease is a rare autosomal dominant syndrome caused by mutations in VHL tumor expressor gene on chromosome 3 [1]. VHL disease is characterized by the development of a variety of benign and malignant tumors. About 40 different lesions in 14 different organs have been described, including pheochromocytomas, epididymal cystadenomas, retinal and central nervous system hemangioblastomas, renal cysts and tumors, endolymphatic sac tumors, and pancreatic cysts [2]. The total systemic number of VHL manifestations rises linearly, with an average of seven VHL-related manifestations at age 60 years [3]. A specific imaging tool for detecting all synchronous VHL-related disease could avoid invasive biopsies.



Publication History

Article published online:
19 March 2020

© Georg Thieme Verlag KG
Stuttgart · New York

 

  • References

  • 1 Maher ER, Neumann HP, Richard S. von Hippel-Lindau disease: a clinical and scientific review. European journal of human genetics: EJHG 2011; 19: 617-623
    CrossrefPubMedGoogle Scholar
  • 2 Lonser RR, Glenn GM, Walther M. et al. von Hippel-Lindau disease. Lancet 2003; 361: 2059-2067
    CrossrefPubMedGoogle Scholar
  • 3 van der Horst-Schrivers ANA, Sluiter WJ, Kruizinga RC. et al. The incidence of consecutive manifestations in Von Hippel-Lindau disease. Fam Cancer 2019; 18: 369-376
    CrossrefPubMedGoogle Scholar
  • 4 Lonser RR, Glenn GM, Walther M. et al. von Hippel-Lindau disease. Lancet 2003; 361: 2059-2067
    CrossrefPubMedGoogle Scholar
  • 5 Prasad V, Tiling N, Denecke T. et al. Potential role of (68)Ga-DOTATOC PET/CT in screening for pancreatic neuroendocrine tumour in patients with von Hippel-Lindau disease. European journal of nuclear medicine and molecular imaging 2016; 43: 2014-2020
    CrossrefPubMedGoogle Scholar
  • 6 Ambrosini V, Campana D, Allegri V. et al. 68Ga-DOTA-NOC PET/CT detects somatostatin receptors expression in von hippel-lindau cerebellar disease. Clinical nuclear medicine 2011; 36: 64-65
    CrossrefPubMedGoogle Scholar
  • 7 Banezhad F, Kiamanesh Z, Emami F. et al. 68Ga DOTATATE PET/CT Versus 18F-FDG PET/CT for Detecting Intramedullary Hemangioblastoma in a Patient With Von Hippel-Lindau Disease. Clinical nuclear medicine 2019; 44: e385-e387
    CrossrefPubMedGoogle Scholar
  • 8 Mukherjee A, Karunanithi S, Bal C. et al. 68Ga DOTANOC PET/CT aiding in the diagnosis of von Hippel-Lindau syndrome by detecting cerebellar hemangioblastoma and adrenal pheochromocytoma. Clinical nuclear medicine 2014; 39: 920-921
    CrossrefPubMedGoogle Scholar
  • 9 Papadakis GZ, Millo C, Jassel IS. et al. 18F-FDG and 68Ga-DOTATATE PET/CT in von Hippel-Lindau Disease-Associated Retinal Hemangioblastoma. Clinical nuclear medicine 2017; 42: 189-190
    CrossrefPubMedGoogle Scholar
  • 10 Sizdahkhani S, Feldman MJ, Piazza MG. et al. Somatostatin receptor expression on von Hippel-Lindau-associated hemangioblastomas offers novel therapeutic target. Eur J Radiol 2019; 112: 130-135
    PubMedGoogle Scholar
  • 11 Shell J, Tirosh A, Millo C. et al. The utility of 68Gallium-DOTATATE PET/CT in the detection of von Hippel-Lindau disease associated tumors. Eur J Radiol 2019; 112: 130-135
    CrossrefPubMedGoogle Scholar